Genentech Bites Back. . .
Executive Summary
A December 1996 US Court of Appeals ruling opened the door for companies such as Eli Lilly and Novo Nordisk to compete with Genentech on human growth hormone, currently a $200 million franchise. But Genentech has fought back, at least against Novo Nordisk, by hiring the executive most familiar with Novo's strategy to sell hGH.
You may also be interested in...
Taking Genentech to the Next Level
Between 1995 and 1999, Genentech focused on getting products to market and spent heavily on clinical development. That investment helped produce an impressive product pipeline that is the envy of the industry. But now it faces some major challenges as it attempts to increase its stature as a global player and prepares to sell its first mass market product.To help it achieve its ambitious goals, Genentech brought in Myrtle Potter, who has held senior management positions at Merck and Bristol-Myers Squibb, as COO and EVP, Commercial Operations.In this interview, Potter argues that Genentech's success in integrating the commercial and scientific ends of the business will serve the company well as it ramps up its commercial capabilities. She also says that because Genentech is facing head-to-head competition for the first time, it will require dramatically new commercialization strategies.
Cosmetic Talc Stakeholders Should Be Watching US EPA Asbestos Developments In 2021
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.
QUOTED. 28 January 2021. Andrea Riposat.
L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.
Need a specific report? 1000+ reports available
Buy Reports